Collaborate with us!

Regenerative Therapy in Parkinson’s Disease

InnoMedica is a Swiss biotech company pioneering in patent-protected nano-transport systems designed to deliver active ingredients with higher precision and improved biodistribution.  

Talineuren, a liposomal formulation of the endogenous ganglioside GM1, is InnoMedica’s flagship neurotherapeutic program. Recent Phase I clinical trial results (NEON trial) presented at AD/PD indicate 

• a favourable safety profile with manageable infusion reactions.
• consistent improvement and stabilization of of UPDRS total scores over up to nearly three years in treated patients (secondary endpoint). 

Based on these results, a placebo-controlled proof of concept study that is currently in preparation (LIBRA trail). Ongoing clinical investigations assess effects after treatment stop, potentially elucidating disease-modifying effects. 

Collaboration Opportunities 

o advance Talineuren to its full potential, InnoMedica is continuously looking for synergies. Whether you are a clinician, basic scientist, investor, or strategic partner in pharma, we invite you to engage on opportunities though collaborating with InnoMedica on Talineuren: 

Clinical development and basic research 

• Participation in future international studies, e.g. as principal investigator, study center or CRO 
• Novel methods to assess Parkinson’s Disease, e.g. through digital biomarkers such as wearables 
• Approaches to show disease modification in Parkinson’s Disease 
• Research on efficacy biomarkers in Parkinson’s disease 
• Use of Talineuren in novel in vitro or in vivo models for Parkinson’s Disease 
• Mechanistic research on the active principle and drug delivery of Talineuren 
• Research on Talineuren in indications beyond Parkinson’s Disease, e.g. in Alzheimer’s Disease, lysosomal storge diseases or amyotrophic lateral sclerosis (ALS) 

Business Development 

• Codevelopment partnerships, e.g. for digital biomarkers 
• Collaboration in the internationalization of Talineuren, including licensing of Talineuren for regional markets 
• Collaboration in the expansion of indications, e.g. for ALS, including licensing of indications 
• Asset financing for the Talineuren program, milestone-based financing, investments in exchange for rights of first negotiation (ROFN) etc. 
• ollaborations based on InnoMedica’s expertise in development of liposomal formulations, including in-house GMP production 

… and we are open for further collaboration opportunities! 

We are eager to bring research expertise and business development together to innovate the treatment of Parkinson’s Disease.   

Interested, questions? Your contact: 

• Andreas Schittny, Manager Regulatory Affairs, InnoMedica Switzerland AG, AD/PD 2026 participant 
• Stéfan Halbherr, CEO, InnoMedica Holding AG

Collaboration Opportunities 

• A recent IQVIA asset valuation of Talineuren estimated risk-adjusted NPV (10y from launch of Talineuren) of USD 0.5 billions today and USD 2.3 billions after phase II. 

AD/PD Poster 2026 – TLN-1 in Parkinson’s disease

Business Case Neurology – Fall 2025